MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$4,050K
Net Income
-$56,160K
Net Profit Margin
-1386.67%
EPS
-$0.18
Unit: Thousand (K) dollars
Revenue Breakdown
Research Fees
Licensing And Royalty Revenue
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue
4,050
8,315
44,854
8,955
Research and development
45,987
46,662
50,092
55,028
Sales and marketing
-
-
-
2,906
Sales, general and administrative
-
-
25,976
22,052
Sales, general, and administrative
13,850
12,334
-
-
Depreciation, amortization, and impairment
-
-
-2,634
5,247
Depreciation and amortization
6,990
6,838
-
-
Total operating expenses
66,827
65,834
73,434
85,233
Loss from operations
-62,777
-57,519
-28,580
-76,278
Interest and other
-42
3,643
5,921
6,765
Grants and incentives
3,854
4,339
3,316
2,729
Other (note 15)
-
-
-156
-1,984
Total other income
3,812
7,982
9,081
7,510
Loss before income tax
-58,965
-49,537
-19,499
-68,768
Income tax recovery
-3,538
-6,372
-10,554
-11,649
Net loss
-55,427
-43,165
-8,945
-57,119
Foreign currency translation adjustment
-733
1,815
-1,536
-41
Comprehensive loss
-56,160
-41,350
-10,481
-57,160
Basic EPS
-0.18
-0.14
-0.035
-0.19
Diluted EPS
-0.18
-0.14
-0.035
-0.19
Basic Average Shares
305,557,294
303,074,605
299,751,890
298,875,174
Diluted Average Shares
305,557,294
303,074,605
299,751,890
298,875,174
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$56,160K
(-84.82%↓ Y/Y)
Net loss
-$55,427K
(-59.61%↓ Y/Y)
Foreign currency
translation adjustment
-$733K
(-116.89%↓ Y/Y)
Income tax recovery
-$3,538K
(-118.80%↓ Y/Y)
Grants and incentives
$3,854K
(4.39%↑ Y/Y)
Loss before income
tax
-$58,965K
(-62.24%↓ Y/Y)
Total other income
$3,812K
(-71.21%↓ Y/Y)
Research Fees
$3,901K
(-41.24%↓ Y/Y)
Licensing And Royalty
Revenue
$149K
Interest and other
-$42K
Loss from operations
-$62,777K
(-26.60%↓ Y/Y)
Total revenue
$4,050K
(-76.29%↓ Y/Y)
Total operating
expenses
$66,827K
(0.24%↑ Y/Y)
Research and development
$45,987K
(17.27%↑ Y/Y)
Sales, general, and
administrative
$13,850K
Depreciation and
amortization
$6,990K
Buy us a coffee
AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. (ABCL)